Fluorine »
PDB 2y1x-2z5z »
2yfx »
Fluorine in PDB 2yfx: Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
Enzymatic activity of Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
All present enzymatic activity of Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib:
2.7.10.1;
2.7.10.1;
Protein crystallography data
The structure of Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib, PDB code: 2yfx
was solved by
M.Mctigue,
Y.Deng,
W.Liu,
A.Brooun,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
| Resolution Low / High (Å) | 36.04 / 1.70 |
| Space group | P 21 21 21 |
| Cell size a, b, c (Å), α, β, γ (°) | 51.721, 57.174, 105.253, 90.00, 90.00, 90.00 |
| R / Rfree (%) | 20.8 / 23.4 |
Other elements in 2yfx:
The structure of Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib also contains other interesting chemical elements:
| Chlorine | (Cl) | 2 atoms |
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
(pdb code 2yfx). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total only one binding site of Fluorine was determined in the Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib, PDB code: 2yfx:
In total only one binding site of Fluorine was determined in the Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib, PDB code: 2yfx:
Fluorine binding site 1 out of 1 in 2yfx
Go back to
Fluorine Binding Sites List in 2yfx
Fluorine binding site 1 out
of 1 in the Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib within 5.0Å range:
|
Reference:
Q.Huang,
T.W.Johnson,
S.Bailey,
A.Brooun,
K.D.Bunker,
B.J.Burke,
M.R.Collins,
A.S.Cook,
J.J.Cui,
K.N.Dack,
J.G.Deal,
Y.Deng,
D.Dinh,
L.D.Engstrom,
M.He,
J.Hoffman,
R.L.Hoffman,
P.S.Johnson,
R.S.Kania,
H.Lam,
J.L.Lam,
P.T.Le,
Q.Li,
L.Lingardo,
W.Liu,
M.W.Lu,
M.Mctigue,
C.L.Palmer,
P.F.Richardson,
N.W.Sach,
H.Shen,
T.Smeal,
G.L.Smith,
A.E.Stewart,
S.Timofeevski,
K.Tsaparikos,
H.Wang,
H.Zhu,
J.Zhu,
H.Y.Zou,
M.P.Edwards.
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. J.Med.Chem. V. 57 1170 2014.
ISSN: ISSN 0022-2623
PubMed: 24432909
DOI: 10.1021/JM401805H
Page generated: Mon Jul 14 15:00:35 2025
ISSN: ISSN 0022-2623
PubMed: 24432909
DOI: 10.1021/JM401805H
Last articles
Mn in 5TYWMn in 5TYV
Mn in 5TIS
Mn in 5TYU
Mn in 5TWQ
Mn in 5TIR
Mn in 5TG3
Mn in 5TSN
Mn in 5TB9
Mn in 5TB8
